ITCI Intra-Cellular Therapies
- 83.520
- +0.040+0.05%
- 83.480
- -0.040-0.05%
Intra-Cellular Therapies News
Jefferies Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Maintains Target Price $105
Mizuho Securities Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Announces Target Price $100
RBC Capital Sticks to Their Buy Rating for Intra-Cellular Therapies (ITCI)
UBS Maintains Intra-Cellular Therapies(ITCI.US) With Hold Rating, Raises Target Price to $87
Intra-Cellular Therapies Is Maintained at Overweight by JP Morgan
J.P. Morgan Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Raises Target Price to $89
Intra-Cellular Therapies Receives Buy Rating Amid Promising Sales Projections and Strategic Developments
A Quick Look at Today's Ratings for Intra-Cellular Therapies(ITCI.US), With a Forecast Between $90 to $102
A Quick Look at Today's Ratings for Intra-Cellular Therapies(ITCI.US), With a Forecast Between $79 to $135
Needham Reiterates Buy on Intra-Cellular Therapies, Maintains $100 Price Target
Intra-Cellular Therapies Analyst Ratings
Jefferies Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Maintains Target Price $105
Analysts Offer Insights on Healthcare Companies: Intra-Cellular Therapies (ITCI), Amylyx Pharmaceuticals Inc (AMLX) and Intuitive Surgical (ISRG)
Morgan Stanley Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Raises Target Price to $95
Jefferies Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Maintains Target Price $105
Jefferies Keeps Their Buy Rating on Intra-Cellular Therapies (ITCI)
Intra-Cellular Therapies Analyst Ratings
Intra-Cellular Therapies Price Target Maintained With a $130.00/Share by Cantor Fitzgerald
Stock Moves Reflect Downgrade for US Economic Growth Outlook - Goldman
Intra-Cellular Therapies Raised to Overweight From Neutral by Piper Sandler
No Data